MedPlus targets 800 new stores in FY27, private label margins recover
Management guides same-store sales growth of 9-10% annually and zero external debt. Private label contribution to rise 20-30 bps per quarter.
— 1 earlier story on Medplus Health Services Ltd. →What's new with Medplus Health Services Ltd.
- Targets 800 net new store additions in FY27, accelerating from prior pace.
- Private label growth to resume at 20-30 bps quarterly margin expansion.
- Same-store sales growth guided at 9-10% annualized.
Why this matters for Medplus Health Services Ltd.
MedPlus has zero external debt, giving it financial flexibility to fund aggressive expansion. The specificity on private label margins and same-store growth provides a clear near-term earnings trajectory, making this concall more substantive than a routine update.
What we're watching
- Execution pace on 800 new stores amid competitive pharmacy landscape.
- Whether private label margin expansion materializes as guided.
- Consistency of same-store sales growth in a high-inflation environment.
The full read
MedPlus used its post-results concall to lay out a detailed growth roadmap. The centrepiece: 800 net new stores in FY27, a step up from recent run rates. That expansion is underpinned by zero external debt—all interest is lease-related under Ind AS, leaving the balance sheet clean for organic investment. Private label, a key margin lever, is expected to add 20-30 basis points per quarter after a pause. Same-store sales are pegged at 9-10% annual growth. The numbers are more concrete than typical guidance and give investors a clear benchmark to track. The open question is whether the pace of store additions can be sustained without cannibalising existing locations or pressuring unit economics.